| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received December 26, 2007
Accepted on January 22, 2008
ORIGINAL ARTICLES |
Division of Nephrology, Veterans Affairs North Texas Health Care System and University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
1 To whom correspondence should be addressed. E-mail: robert.reilly2{at}va.gov.
 |
Abstract |
|---|
Background and objectives: Recent studies strongly link nephrogenic systemic fibrosis to gadolinium administration for magnetic resonance imaging. In a recent advisory, the Food and Drug Administration stated that all gadolinium-containing chelates are potentially associated with nephrogenic systemic fibrosis; however, most reported cases are linked to gadodiamide (Omniscan) and gadopentetate dimeglumine (Magnevist). Given the severe consequences of nephrogenic systemic fibrosis, it is critical to define the risks associated with each gadolinium-containing chelate. The purpose of this study was to examine nephrogenic systemic fibrosis risk in a hemodialysis population exposed to gadoteridol (ProHance).
Design, setting, participants, & objectives: Appointment logs were used to generate a database of all long-term hemodialysis patients at the Dallas Veterans Affairs hospital since August 2001. These patients were then examined in the Veterans Affair’s electronic medical record system for gadolinium exposure during magnetic resonance imaging from 2000 through 2007, a period during which gadoteridol was the sole contrast agent used.
Results: A total of 141 patients were identified with 198 gadoteridol exposures. No cases of nephrogenic systemic fibrosis were identified. The observed frequency of nephrogenic systemic fibrosis was compared with the expected frequency (2.4%) using one-way 
2 and binomial analysis, yielding a P < 0.05, indicating that the result was not explained by chance alone.
Conclusions: It is concluded that the risk for nephrogenic systemic fibrosis with gadoteridol in patients who are on long-term hemodialysis may be lower than with gadodiamide and gadopentetate dimeglumine.
Related Article
This article has been cited by other articles:
|
|
 |
|
  H. H. Abujudeh, R. Kaewlai, A. Kagan, L. B. Chibnik, R. M. Nazarian, W. A. High, and J. Kay Nephrogenic Systemic Fibrosis after Gadopentetate Dimeglumine Exposure: Case Series of 36 Patients Radiology, October 1, 2009; 253(1): 81 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kribben, O. Witzke, U. Hillen, J. Barkhausen, A. E. Daul, and R. Erbel Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J. Am. Coll. Cardiol., May 5, 2009; 53(18): 1621 - 1628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Runge Gadolinium and Nephrogenic Systemic Fibrosis Am. J. Roentgenol., April 1, 2009; 192(4): W195 - W196. [Full Text] [PDF]
|
|
|
|
|
|
P. M. Colletti Reply Am. J. Roentgenol., April 1, 2009; 192(4): W197 - W197. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Perazella Current Status of Gadolinium Toxicity in Patients with Kidney Disease Clin. J. Am. Soc. Nephrol., February 1, 2009; 4(2): 461 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. Shellock and A. Spinazzi MRI Safety Update 2008: Part 1, MRI Contrast Agents and Nephrogenic Systemic Fibrosis Am. J. Roentgenol., October 1, 2008; 191(4): 1129 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Colletti Nephrogenic Systemic Fibrosis and Gadolinium: A Perfect Storm Am. J. Roentgenol., October 1, 2008; 191(4): 1150 - 1153. [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Rofsky Nephrogenic systemic fibrosis: considerations for the cardiologist. J. Am. Coll. Cardiol. Img., July 1, 2008; 1(4): 457 - 459. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
